Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB)

Classification of Mutation Characteristics by Whole-Exome Sequencing (WES) in Intraductal Neoplasms of the Bile Duct (IPNB) Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03838913

Acronym

WESIPNB

Enrollment

Registered

2019-02-12

Start date

2019-02-15

Completion date

2019-12-31

Last updated

2019-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Neoplasms, Intraductal Papillary Mucinous Neoplasm

Keywords

Whole-exome Sequencing, intraductal papillary neoplasms of the bile duct, mutation characteristics

Brief summary

Intraductal papillary neoplasm of the bile duct (IPNB) is a distinct type of biliary tumor characterised with delicate fibrovascular stalks (papillary of villous) covered at biliary epithelium. The typical pathologic feature is dramatical dilation of affected bile ducts due to obstruction by mucin production. IPNB has a better prognosis than bile duct carcinoma, but the current proposed entity contains multiple definitions or categories, thus confused in pathology. Although mutations of several genes on IPNBs (such as GNAS, KRAS, APC, CTNNB1, and RNF43) identified in previous studies, there is still an unification at gene expression signature. This research trial will use whole exome sequencing and subsequent bioinformatic analysis in finding causative mutations in deoxyribonucleic acid (DNA) samples from IPNBs patients.

Detailed description

Using production-scale platform, this study will carry out whole exome sequencing from archival (FFPE) material to Identification and classification of significantly mutated genes, determine the somatic genomic alterations that may be relevant to the development or treatment of cancer, establish classification of IPNBs gene mutation signature. Next, analysis of gene mutation signature and IPNBs clinicopathologic outcomes, including the association between pathologic type, long-term oncological outcomes and gene mutation signature. Last, the determination of involved signal pathways at IPNB patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of IPNBs * ECOG Performance status of 0, 1, or 2 * Adequate liver function, bilirubin \< 1.5 times ULN, ALT or AST \< 2.5 times ULN * Adequate renal function: creatinine \< 1.8 * Must be at least 18

Exclusion criteria

* Diagnosis of hepatic mucinous cystadenoma (MCN) * Complicated with other Malignancy * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Identification of novel genetic contributors to IPNBs	1 year	Novel genetic abnormalities that are found to be associated with IPNBs via production-scale platform for whole exome sequencing from archival (FFPE) material. The tumor and normal specimens will be obtained from patients with IPNBs who are receiving treatment at Fujian Provincial Hospital, Fujian Medical University Union Hospital and First affiliated Hospital of Fujian Medical University.
Validation of WES outcomes	1 year	To precise determination of mutation signature of WES results by Sanger Sequencing.
Determination of involved signal pathways	1 year	To predict and verify the involved signal pathways by bioinformatics

Countries

China

Contacts

Primary ContactYaodong Wang, Prof

nanfangg@gmail.com18105010560

Outcome results